Skip to content

Evaluation of effect of Hajrul Yahood in patients with Urolithiasis.

Therapeutic evaluation of Hajrul Yahood (LAPIS JUDAICUS)in patients of Hasat-e-Bauliyah (Urolithiasis)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/04/032559
Enrollment
30
Registered
2021-04-06
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N20-N23- Urolithiasis

Interventions

Intervention1: Hajrul Yahood: Drug will be powdered very finely then it will be cleaned or separated from impurities by process of elutriation or ablution of medicine (ghusl-e-advia).Then Powder of Ha

Sponsors

National Institute of Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with the renal Ureteric stones of size less than 10 mm diagnosed by Ultrasonography of Whole Abdomen & Pelvis or X-ray (if required) abdomen KUB. Both Symptomatic & Asymptomatic urolithiasis patients. Only stable cases of urolithiasis will be enlisted.

Exclusion criteria

Exclusion criteria: Patients having the stone of size more than 10mm. Severe Urinary Tract Infection. Severe Hydrouretronephrosis. Patient having any severe systemic disease. Pregnant and Lactating women. Bladder outlet obstruction.

Design outcomes

Primary

MeasureTime frame
Urine routine & microscopic USG abdomen and pelvis especially KUB X-ray KUB if required Blood urea & serum creatinine Timepoint: 42 days

Secondary

MeasureTime frame
Pain in abdomen Burning micturition Haematuria Nausea Vomiting Timepoint: 42 days.

Countries

India

Contacts

Public ContactDr Mehjabeen Fatimah

National Institute of Unani Medicine.

adilsubooralig13@gmail.com9307439891

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026